S468
Clinical - Gynaecological
ESTRO 2026
AEs were observed in the HYPO and RW EMB- RADcom group without statistical significance. Keywords: Real-world, Cervix, IGABT
Mini-Oral 3327
Quality of Life Analysis of a Phase II randomised controlled trial evaluating adjuvant pelvic radiotherapy using IMRT or 3DRT for endometrial Cancer DARRAGH P BROWNE 1 , Killian Nugent 1 , Mary Burke 1 , Mary Dunne 2 , Bahareh Kohsravi 2 , Lydia O'Sullivan 2 , Aoife M Shannon 3 , Deepti Sharma 3 , Shirley Bradshaw 2 , Orla McArdle 1 , Osama Salib 1 , Naomi Lavan 1 , Charles Gillham 1 1 Radiation Oncology, St Luke's Radiation Oncology Network, Dublin, Ireland. 2 Cancer Trials Unit, St Luke's Radiation Oncology Network, Dublin, Ireland. 3 Cancer Trials Unit, Cancer Trials Ireland, Dublin, Ireland Purpose/Objective: Endometrial cancer (EC) is the 15th most common malignancy worldwide, with over 420,000 documented new cases in 2022(1). With a favourable prognosis, the importance of toxicity minimisation and QOL improvement during and after treatment for EC is readily appreciable. The Cancer Trials Ireland (ICORG) 09-06 trial was designed to compare 3D conformal radiotherapy (3DCRT) with IMRT in the adjuvant treatment of endometrial cancer. Herein we discuss the QOL results (a secondary objective) of this trial. Material/Methods: CTRIAL-IE 09-06 was a prospective phase II randomised trial which investigated the incidence of grade 2 or higher acute GI & GU toxicity in patients receiving adjuvant pelvic radiotherapy (3D compared with IMRT) for endometrial cancer. Eligible participants were all adults aged 18 or over scheduled to receive adjuvant pelvic radiotherapy for histologically confirmed endometrial
Conclusion: Real-world radiation compliance is crucial to achieve comparable outcomes to EMBRACE-II protocol. OTT remains an important factor, particularly when radiation parameters deviate from EMBRACE studies. The higher
Made with FlippingBook - Share PDF online